Despite its immense promise, the field of immuno-oncology yields many failed clinical trials. The key to improving success in development is a translational approach that seeks more predictive data, earlier in the process.

View our webinar to learn about a unique platform of validated in vitro assays, in vivo immune cell profiling, and efficacy models that helps researchers to reliably support compound optimization and selection for in vivo studies, and achieve ultimate clinical success.


  • Shilina Roman, DAP, Group Leader, Integrated Biology, Discovery Services, Charles River